Bluegrass Pharmaceuticals

Bluegrass Pharmaceuticals is a discovery-stage biotechnology company that focuses on developing advanced lipid-based technologies for therapeutic delivery and vaccine enhancement. The company utilizes its proprietary BLITz (Balanced and Long-lived Immunity using Triazine lipids) platform, which employs high-throughput solid-phase synthesis to rapidly generate high-purity lipid nanoparticles (LNPs). This technology is designed to enable targeted delivery to organs such as the brain, spinal cord, lungs, and heart, while also managing immune responses by adjusting leukocyte polarity for therapeutic effect.

The company's primary focus is the commercialization of its lead candidate, BLITz-003, a lipid nanoparticle designed to function as an effective adjuvant in protein-based vaccines. By replacing traditional aluminum salts, BLITz-003 aims to improve vaccine efficacy, reduce the number of required doses, and promote stronger, more durable immunity. Bluegrass Pharmaceuticals operates on a business model centered on out-licensing its technology and assets to established pharmaceutical partners for further clinical development and commercialization, targeting strategic partnerships within the vaccine development industry.